| Issue Type | XXXX |
|---|---|
| Country | Switzerland |
| Industry | XXXX |
| Region | XXXX |
| Maturity Date | 2029-11-13 |
| Par Value | 5000000 |
| Callable | XXXX |
| Next Call Date | XXXX |
| Call Type | XXXX |
| Call Price (%) | XXXX |
| Series | XXXX |
| Class | XXXX |
| Maturity Structure | XXXX |
| Amount Outstanding (mil) | 550.00 |
| Coupon | 0.625 |
|---|---|
| Coupon Type | XXXX |
| Coupon Frequency | XXXX |
| First Coupon Date | XXXX |
| Last Coupon Date | XXXX |
| Sinking Fund | XXXX |
|---|---|
| Security | XXXX |
| Subordination | XXXX |
| Debt Type | XXXX |
| Issue Date | XXXX |
|---|---|
| Dated Date | XXXX |
| Issue Size (mil) | 550 |
| Min. Piece | XXXX |
| Min. Increment | XXXX |
This Novartis AG corporate medium term notes has a X.X % fixed rate coupon paid on a XXXX basis. It was issued on MAR 12, 2000 with an issue size of XXX million CHF and matures on DEC 9, 2000 with a last coupon date of FEB 28, 2020. |
Novartis AG, founded in 1996 and headquartered in Basel, Switzerland, is a leading global healthcare company focused on providing innovative medicines and treatments to improve patients' lives. The company specializes in pharmaceuticals, eye care, and generics, with well-known products including the cancer treatment Gleevec and the heart failure drug Entresto.